News

ABT's compact biomarker generator comes to Russia

April 24, 2014

ABT Molecular Imaging announced this week that its compact "Dose on Demand" Biomarker Generator has been installed in Russia.

April 24, 2014 - The system, which can produce a single dose of FDG in about 20 minutes with the push of a button, is installed at a new state-of-the-art oncology center in St. Petersburg called the Center of Radiosurgery, Stereotactic Radiotherapy and Oncology. The installation was made possible in part through cooperation with the Diagnostic and Treatment Center of the International Institute of Biological Systems (DTC IIBS) in St. Petersburg and its U.S. representative, Owen Kane Molecular Imaging Inc.

DTC IIBS is the leading provider of diagnostic services in the Russian Federation, with a network of 80 imaging centers located in more than 60 cities in Russia. 

"We are very proud of our relationship with DTC IIBS, and truly excited that we are a part of their expansion in molecular imaging", said Peter Kingma, president and CEO of ABT Molecular Imaging, which is headquartered in Knoxville, Tenn. "We believe that our BG-75 is particularly well matched to the growing clinical demands of Russia, and look forward to supporting this innovative company as it continues to expand in the future." 

Dr. Arkadi Stolpner, chief executive officer of DTC IIBS, and Philip F. Jacobus of Owen Kane said that the ABT BG-75 is uniquely suited for the Russian market. 

ABT's Biomarker Generator is ideal for a market that's looking for local production of FDG when a network pharmacy is not available. 

Traditional PET pharmaceutical production is normally done in a large center — typically four thousand square feet. But this system fits into a room that can be as small as 350 square feet. 

Radiopharmaceuticals are used in PET imaging. Most procedures use FDG — a molecule of glucose attached artificially to an A18 fluorine atom — which emits a positron that combines with the electron and highlights an area on an image to help physicians get information about the current progress of the disease, evaluate treatment outcomes, and adjust individual cancer treatment plans for patients. 

The Biomarker Generator has not yet been cleared in the U.S. for use in the clinical setting on humans. Only two U.S. hospitals have one for preclinical imaging.

 


Other News

View the latest updates from ABT Molecular Imaging